Problem being addressed[edit | edit source]
Pre-eclampsia affects over three million mothers worldwide each year and is also associated with premature birth. Regular blood pressure (BP) monitoring is a cost-effective means of identifying hypertensive diseases in their early stages. However, there are currently no effective ways to detect a women's likelihood to suffer from pre-eclampsia prior to developing the condition.
Detailed description of the solution[edit | edit source]
The research done to advance this device is the first major development of a reliable biomarker diagnostic that can accurately predict the onset of pre-eclampsia. The presence of this biomarker also strongly suggests that pre-eclampsia is characterized by abnormal placenta formation which limits the amount of oxygen that can be delivered to the developing fetus during pregnancy. If these biomarkers can detect pre-eclampsia at its earliest stages, there is a high likelihood that maternal and infant death resulting from this condition can be reduced.
Designed by[edit | edit source]
- Designed by: Dr. Isabella Caniggia of the Samuel Lunenfeld Research Institute
- Manufacturer location: Manitoba, Canada
Funding Source[edit | edit source]
Miraculins, Inc.
References[edit | edit source]
Other internally generated reports[edit | edit source]
Miraculins Inc. (2013, March 11). Miraculins to License Additional Preeclampsia Technology from Mount Sinai Hospital. Retrieved from here
Externally generated reports[edit | edit source]
Miraculins Inc. (2010, July 13). Miraculins Announces Issuance of Important Preeclampsia Patent in United States. Marketwired.com. Retrieved from here
(2013). Miraculins Pre-Eclampsia Markers. Mandate. Retrieved from here
IP and copyright[edit | edit source]
US Patent 7,754,495 entitled "Methods for Early Diagnosing of an Increased Risk of Preeclampsia"